|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001779,
umls-concept:C0008976,
umls-concept:C0025219,
umls-concept:C0030685,
umls-concept:C0033139,
umls-concept:C0034656,
umls-concept:C0036043,
umls-concept:C0087111,
umls-concept:C0205227,
umls-concept:C0391871,
umls-concept:C0439231,
umls-concept:C0439590,
umls-concept:C0680255,
umls-concept:C1283071,
umls-concept:C1696465,
umls-concept:C1963578,
umls-concept:C2587213,
umls-concept:C2698872
|
|
pubmed:dateCreated |
2010-9-3
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Melatonin is extensively used in the USA in a non-regulated manner for sleep disorders. Prolonged release melatonin (PRM) is licensed in Europe and other countries for the short term treatment of primary insomnia in patients aged 55 years and over. However, a clear definition of the target patient population and well-controlled studies of long-term efficacy and safety are lacking. It is known that melatonin production declines with age. Some young insomnia patients also may have low melatonin levels. The study investigated whether older age or low melatonin excretion is a better predictor of response to PRM, whether the efficacy observed in short-term studies is sustained during continued treatment and the long term safety of such treatment.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1741-7015
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
51
|
|
pubmed:dateRevised |
2011-1-24
|
|
pubmed:meshHeading |
pubmed-meshheading:20712869-Adolescent,
pubmed-meshheading:20712869-Adult,
pubmed-meshheading:20712869-Age Factors,
pubmed-meshheading:20712869-Aged,
pubmed-meshheading:20712869-Aged, 80 and over,
pubmed-meshheading:20712869-Delayed-Action Preparations,
pubmed-meshheading:20712869-Double-Blind Method,
pubmed-meshheading:20712869-Female,
pubmed-meshheading:20712869-Humans,
pubmed-meshheading:20712869-Male,
pubmed-meshheading:20712869-Melatonin,
pubmed-meshheading:20712869-Middle Aged,
pubmed-meshheading:20712869-Placebos,
pubmed-meshheading:20712869-Quality of Life,
pubmed-meshheading:20712869-Sleep,
pubmed-meshheading:20712869-Sleep Initiation and Maintenance Disorders,
pubmed-meshheading:20712869-Treatment Outcome,
pubmed-meshheading:20712869-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety.
|
|
pubmed:affiliation |
CPS Research, Glasgow, UK. alangwade@fastmail.fm
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
